NCT05709210Active, not recruiting
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 71 (actual)
- First submitted
- 24 Jan 2023
- Start date
- 20 Jul 2023
- Primary completion date
- 2 Oct 2026
- Lead sponsor
- Poitiers University Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT05709210
What you commit to
- Study type: Interventional
- Participants enrolled: 71
- From 20 Jul 2023 to the primary completion date, 2 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other neurodegenerative condition (Parkinson's disease, Lewy body disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis)
- Severe anxiety or depressive disorder HADS score ≥ 17
- Terminal phase of a severe disease
- Evidence of a lesion on MRI that may be involved in cognitive impairment
Other
- Inability to perform MMSE or MMSE \< 20 ;
Who the study is looking for
- Patient consulting in routine care in one of the CMRR
- No sensory impairment that may compromise smartphone use
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.